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Abstract
MicroRNAs (miRNAs) are endogenous, small, noncoding single-stranded RNA molecules approximately 22
nucleotides in length. miRNAs are involved in the post-transcriptional regulation of various important cellular
physiological and pathological processes, including cell proliferation, differentiation, apoptosis, and hormone
biosynthesis and secretion. Ovarian follicles are the key functional units of female reproduction, and the
development of these follicles is a complex and precise process accompanied by oocyte maturation as well as
surrounding granulosa cell proliferation and differentiation. Numerous miRNAs expressed in the ovary regulate
ovarian follicle growth, atresia, ovulation and steroidogenesis and play an important role in ovarian disorders. This
review considers recent advances in the identification of miRNAs involved in the regulation of ovarian function as
well as the possible influence of miRNAs on ovarian-derived disorders, such as ovarian cancer, polycystic ovarian
syndrome and premature ovarian failure. An improved understanding of the regulation of ovarian function by
miRNAs may shed light on new strategies for ovarian biology and ovarian disorders.
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Discovered in 1993 by Ambros and colleagues, micro-
RNAs (miRNAs) are endogenous, small, noncoding
single-stranded RNA molecules 22–24 nucleotides (nt)
in length [1]. Primary miRNA transcripts (pri-miRNAs)
are several kilobases long and undergo substantial pro-
cessing in the nucleus, resulting in the generation of a
70- to 90-nt stem-loop precursor miRNA (pre-miRNA).
Pre-miRNAs undergo substantial processing by Dicer, a
double-stranded miRNA duplex, to form mature miR-
NAs. Mature miRNAs play pivotal roles in regulating
translation by binding to the 3′-untranslated regions
(3′-UTRs) of their target mRNAs [1–4]. Exosome-
mediated miRNA transfer is a major mechanism of
genetic exchange between cells [5]. Kosaka et al. re-
ported that circulatory miRNAs are released with exo-
somes, including miRNAs, mRNAs and proteins, and
are subsequently transferred to recipients to resume
their functions [6].
miRNAs are involved in the regulation of various im-
portant cellular physiological and pathological processes,
including cell proliferation, differentiation, apoptosis,
and hormone biosynthesis and secretion [5, 7]. The
human ovary contains approximately 10,000 primordial
follicles at birth that are prepared for the long duration
of the fertile period. Folliculogenesis and steroidogenesis
are complex processes involving intraovarian gene expres-
sion, signaling pathways, and endocrine and paracrine fac-
tors [8, 9]. The phosphorylation and tensin homolog
deleted on chromosome ten/phosphatidylinositol-3 kin-
ase/protein kinase B (PTEN/PI3K/Akt) signaling pathway
contributes to oocyte proliferation, survival, migration and
metabolism [10]. Wingless-type MMTV integration site
family member 4 (WNT4) is required for antral follicle
development by regulating granulosa cell functions [11],
the transforming growth factor β (TGF-β) superfamily
members (including GDF9, growth differentiation factor 9
and BMP15, bone morphogenetic protein 15) are major
regulators of follicle development [12], and miRNAs are
involved in granulosa cell proliferation and apoptosis [13].
Here, we review recent findings regarding miRNA ex-
pression profiles in the ovary and the potential roles of
miRNA in ovarian function and ovarian disorders. We
believe that a better understanding of ovarian miRNA
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miRNA profiles in the ovary
miRNAs are expressed in the ovary and are involved in
the regulation of mammalian reproduction. miRNA
expression profiles have been identified in numerous
species (Additional file 1: Table S1), including human,
mouse, bovine, sheep, chicken, fish, swine and equine
species [14–21]. Timoneda et al. performed a systematic
study of porcine miRNA expression and found that let-
7a, miR-25 and miR-106a are preferentially expressed in
the ovary [22]. Li et al. [21] evaluated the miRNA tran-
scriptome in the adult porcine ovary and testis via deep
sequencing technology. They reported that miR-21-5p,
miR-143-3p and members of the let-7 family were the
top unique miRNAs for both the ovary and testis and
that these miRNAs play cellular housekeeping roles dur-
ing ovarian and testicular development. miR-378, miR-1,
miR-206, miR-379, miR-127, and miR-411 are downreg-
ulated in the ovary compared with the testis; by contrast,
miR-10b, miR-26a, miR-21, miR-140, and miR-101 are
upregulated in the ovary but not in the testis. Further-
more, most of the differentially expressed miRNAs
located on the X chromosome (X-linked miRNAs) are
significantly upregulated in the ovary compared with the
testis and are co-expressed with X-linked miRNAs. Re-
gardless of species, the let-7 family, miR-21, miR-99a,
miR-125b, miR-126, miR-143, miR-145, and miR-199b
are the most predominant miRNA populations in the
ovary [23].
miRNA expression is organ specific and closely re-
lated to organ function, particularly in the ovary. The
ovary contains oocytes and multiple somatic cell types
such as granulosa cells, theca cells and cumulus cells.
The expression and function of miRNAs are associated
with different cell types (Additional file 2: Table S2). In
total, 58 miRNAs are predominantly expressed in the bo-
vine fetal ovary compared with somatic tissue. Among
them, eight miRNAs (bta-miR-99a, bta-miR-10b, bta-miR-
199a-3p, bta-miR-199a-5p, bta-miR-424, bta-miR-100,
bta-miR-455, and bta-miR-214) are expressed at a 10-fold
greater level in the fetal bovine ovary compared with som-
atic tissue pools. Further analyses indicate that bta-miR-
424 and bta-miR-10b are highly abundant in germinal
vesicle (GV) oocytes [20]. Such expression patterns indi-
cate that these miRNAs are maternally inherited and may
potentially be involved in the maternal transcript turnover
during zygotic gene activation. Various miRNAs are in-
volved in oocyte maturation, such as miR-2, miR-7,
miR-184, miR-100, miR-9b, let-7, miR-79, miR-133,
miR-275 and miR-252 [24–26]. In different stages of
the oocytes, miRNA expression has been shown to
differ. miR-2 and miR-133 are considerably more abun-
dant in the first metaphase (MI) compared with the GV
stage, and they both inhibit cyclin B translation by
downregulating the 3′-UTRs of the crab cyclin B gene
[25]. Some miRNAs, such as the let-7 family, play a
housekeeping role in the ovary, independent of species
[21, 27]. miRNA in granulosa cells is expressed differen-
tially in the follicular and luteal stages. miR-503 has been
found to be downregulated during the FSH-responsive
follicular development stage and luteinization and upregu-
lated during the later stage before ovulation [28].
In characterizing the miRNA profile in human cumu-
lus granulosa cells (CGCs), Xu et al. demonstrated that
the let-7 family was the most abundant miRNA in these
cells in both polycystic ovarian syndrome (PCOS)
patients and normal cycling women [27]. Compared
with normal cycling women, miR-10a-5p, miR-1307-3p,
miR-423-5p, miR-1273 g-3p, miR-199a-3p, miR-185-5p,
and miR-483-5p are upregulated in the CGCs of PCOS
patients, and miR-483-5p suppresses Notch3 and
mitogen-activated protein kinase 3 (MAPK3) expres-
sion in human CGCs by directly binding the 3′-UTRs
of Notch3 and MAPK3 mRNA [27].
Bioinformatics and Gene Ontology analysis revealed
that the target genes of these predominantly expressed
miRNAs in the ovary are involved in cell cycle regulation;
cellular growth, proliferation and apoptosis; endocrine sys-
tem disorders; and ovarian functions [29]. In addition, a
recent study demonstrated that miR-143 inhibited primor-
dial follicle formation by reducing the expression of
cyclin-dependent kinases (CDKs) 4 and 6 and cyclins B1,
D2, and E2 in pregranulosa cells [30]. Furthermore, miR-
181a inhibits mouse ovarian granulosa cell proliferation
by targeting activin receptor IIA [31], and miR-26b pro-
motes ovarian granulosa cell apoptosis by targeting the
ataxia telangiectasia mutated (ATM) gene during follicular
atresia [32]. Finally, miR-132 and miR-212 expression are
associated with hormonal regulation in ovulation and
luteinization [33].
miRNAs and ovarian function
miRNAs and ovarian follicle development
miRNAs are involved in the entire process of ovarian
follicle development, including follicle growth, atresia
and ovulation. In each stage of follicle development, dif-
ferent growth factors contribute to stage-specific func-
tions in different cell types [8, 9]. miRNAs also play an
important role in the regulation of follicular develop-
ment. McBride et al. [19] identified miRNA expression
profiles at different stages of follicle development, in-
cluding small follicles (1.5–3.5 mm), medium follicles
(4.0–5.5 mm), pre-ovulatory follicles, early corpora
lutea, late corpora lutea, and corpus albicans. miR-21,
miR-125b, let-7a and let-7b are the most abundantly
expressed miRNAs across the different development
stages. miR-199a-3p, miR-145 and miR-31 are over-
expressed at the follicular stage and exhibit a marked
decrease in the follicular-luteal transition. By contrast,
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miR-503, miR-21 and miR-142-3p are generally expressed
at lower levels during the follicular stages and exhibit sig-
nificant increases in luteal tissues [19]. Zhang et al. [31]
reported that miR-181a was reduced in preantral and an-
tral follicles of mice compared with primary follicles. miR-
181a suppressed activin receptor IIA (acvr2a) expression
and decreased the phosphorylation of the activin intracel-
lular signal transducer mothers against decapentaplegic
homolog 2 (Smad2) in mice granulosa cells, leading to
regulation of granulosa cell proliferation and ovarian fol-
licle development [31].
Folliculogenesis begins with the breakdown of germ cell
clusters and the formation of primordial follicles. Zhang
et al. revealed that miR-143 was expressed in pregranulosa
cells using in situ hybridization. miR-143 inhibits the for-
mation of primordial follicles by suppressing pregranulosa
cell proliferation and downregulating the expression of
genes related to the cell cycle, including cyclin D2, CDK4
and CDK6 [30]. During folliculogenesis, more than 99 %
of ovarian follicles undergo atresia, and the roles of miR-
NAs in regulating follicle development and atresia were
recently elucidated. Differentially expressed miRNAs were
constructed for healthy, early atretic, and progressively
atretic follicles [32]. Hsa-miR-936, P-miR-1281, hsa-miR-
26b, mmu-miR-1224, hsa-miR-10b, P-miR-466 g-b, P-
miR-1275, hsa-miR-574-5p, R-miR-26b, hsa-miR-149*,
hsa-miR-1275, and hsa-miR-99a are upregulated during
follicle atresia, whereas R-let-7a, hsa-let-7i, hsa-miR-92b,
hsa-miR-92a, P-miR-923, hsa-miR-1979, R-miR-739, hsa-
miR-1308, hsa-miR-1826, P-miR-1826, and ssc-miR-184
are downregulated during this process. miR-26b, which is
upregulated during follicular atresia, increases DNA
breaks and promotes granulosa cell apoptosis by directly
targeting ATM.
Follicle atresia is triggered by granulosa cells apop-
tosis [34, 35]. miRNAs are involved in granulosa cell
apoptosis. miR-34s induces cell apoptosis and growth
arrest through the activation of p53 and the cyclin-
dependent kinase inhibitor p21 [36, 37]. Tu et al. re-
ported that miR-34a promoted granulosa cell apoptosis
in pig ovarian follicles by targeting the inhibin beta B
(INHBB) gene [38]. Carletti et al. reported that miR-21
was highly induced by luteinizing hormone (LH) in
murine granulosa cells and that the suppression of miR-21
activity in vitro caused granulosa cell apoptosis [39].
Advanced reports indicate that miRNA is associated
with oocyte maturation. The oocyte initiates meiosis at
the beginning of DNA synthesis and remains in MI
phase until the resumption of meiosis. Before ovulation,
oocytes become secondary oocytes after completing the
first meiosis and stop at metaphase II (MII) of meiosis
until fertilization [26, 40]. Xiao et al. [26] reported that
transgelin 2 (TAGLN2), which encodes an actin protein,
participates in ovarian development and maturation. In
addition, miR-133b regulates oocyte maturation through
its potential target TAGLN2 at both the transcription
and translation levels.
Dicer is a ribonuclease that is required for the synthesis
and processing of mature functional miRNAs. Dicer is
expressed in both oocytes and granulosa cells of the
mouse ovarian follicle [19]. The role of Dicer in pre-
ovulatory follicle development and ovulation has also
been elucidated. Lei et al. [28] reported that conditional
inactivation of Dicer1 in follicular granulosa cells led to
increased primordial follicle pool endowment, acceler-
ated early follicle recruitment and an increase in degen-
erate follicles in Dicer conditional knockout (cKO)
ovaries. Dicer1 regulates follicle development by down-
regulating miR-503, an ovary-specific miRNA, as well
as miR-503 target genes, such as anti-Müllerian hor-
mone (AMH); inhibin beta A subunit (INHBA); cyto-
chrome P450, family 17, subfamily a, polypeptide 1
(Cyp17a1); cytochrome P450, family 19, subfamily a,
polypeptide 1 (Cyp19a1); zona pellucida glycoproteins
(ZPs); growth differentiation factor 9 (GDF9) and bone
morphogenetic protein 15 (BMP15). Dicer1 inactivation
in female mice causes abnormal follicular morphology
and infertility [28, 40, 41]. These studies demonstrate
that Dicer plays important roles in follicle growth and
oocyte maturation.
Multiple factors are involved in follicle development,
such as the TGF-β superfamily members [42, 43], Ligand
stimulation of type I (also referred to as activin receptor-
like kinases (ALKs)) and Smads [44–46]. miRNA regulates
follicle development by affecting these factors. A recent
study revealed that miR-224 expression is regulated by the
TGF-β/Smad pathway. miR-224 overexpression enhances
TGF-β1-induced granulosa cell proliferation by targeting
Smad4, which is a key regulator involved in ovarian follicle
growth and female fertility, whereas inhibition of en-
dogenous miR-224 partially suppresses TGF-β1-induced
granulosa cell proliferation, indicating an important bio-
logical role of miR-224 in regulating gene expression dur-
ing folliculogenesis [47].
miRNAs also influence ovulation indirectly. Hasuwa
et al. examined the role of miR-200b and miR-429 in ano-
vulation and infertility in female mice [48]. miR-200b and
miR-429 suppressed the expression of zinc-finger E-box
binding homeobox 1 (ZEB1) in the pituitary gland where
these miRNAs are highly expressed; moreover, miR-200b
and miR-429 inactivation restrained LH biosynthesis, sug-
gesting that miR-200b and miR-429 support ovulation by
indirectly functioning in the hypothalamus-pituitary-
ovarian axis.
miRNAs and ovarian steroidogenesis
Folliculogenesis is a highly dynamic process that is closely
associated with alterations in circulating hormone levels.
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Given the indispensable role of miRNAs in ovarian follicle
development and female fertility, the relationships be-
tween ovarian hormones and miRNAs have recently been
investigated. A study on granulosa/cumulus cells reported
the expression of several miRNAs (miR-23a, miR-23b,
miR-542-3p, miR-211, and miR-17-5p) in ovarian somatic
cells, and the authors speculated that miRNA target genes,
including cyclooxygenase-2, steroidogenic acute regula-
tory protein (StAR), and CYP-19A1 (aromatase), regulate
granulosa/theca cells proliferation, differentiation and
steroid biosynthesis [43].
miRNAs regulate ovarian steroid hormones by targeting
hormone receptors as well as affecting hormone biosyn-
thesis and release. For example, estradiol (E2) plays an im-
portant role in ovarian follicle development, and the
production of E2 is tightly controlled by aromatase. Xu
et al. reported that aromatase expression and estradiol
synthesis in granulosa cells are post-transcriptionally
downregulated by miR-378 and that miR-378 affects estra-
diol synthesis by binding the 3′-UTR of the aromatase
coding sequence [49]. Conversely, miR-133b stimulates
ovarian estradiol synthesis by targeting Foxl2, which
mediates the transcriptional repression of StAR and
CYP19A1 to promote estradiol biosynthesis [50]. miR-
NAs not only regulate estradiol synthesis but also estra-
diol release. Estradiol release is promoted by miR-383
in ovarian granulosa cells, and miR-383 inhibits RNA
binding motif single-stranded interacting protein 1
(RBMS1) by altering its mRNA stability, leading to the
inactivation of c-Myc and steroidogenesis in granulosa
cells [51]. Finally, miR-423-5p and miR-378 regulate es-
tradiol synthesis by targeting CYP19A1 mRNA and
repressing CYP19A1 protein content and enzyme activ-
ity in newborn piglets [52].
Conversely, the miRNA expression profile is pro-
foundly influenced by circulating hormones. miR-132
and miR-212 expression are increased following human
chorionic gonadotropin (HCG) induction [33], and the
expression of 31 microRNAs is altered after follicle-
stimulating hormone (FSH) treatment. Specifically,
miR-29a and miR-30d expression is downregulated in
the short term but upregulated in the long term follow-
ing FSH induction [53].
Sirotkin et al.[54] first demonstrated that miRNAs con-
trol reproductive functions, resulting in enhanced or
inhibited release of ovarian progestagen and androgen.
Thirty-six miRNAs, including let-7b, let-7c, miR-15a,
miR-17-3p, miR-96, miR-92, miR-108, miR-133b, miR-
134, miR-135, and miR-146, inhibited progesterone
release, whereas 16 miRNAs (miR-16, miR-24, miR-25,
miR-122, miR-145, miR-182, miR-18, miR-125a, miR-147,
miR-32, miR-103, miR-143, miR-150, miR-152, miR-153
and miR-191) promoted progesterone release in granulosa
cells. In addition, let-7a, let-7b, let-7c, miR-16, miR-17-3p,
miR-24, miR-25, miR-26a, mir-108, and mir-122 inhibited
testosterone release.
Moreover, pathological factors significantly influence
miRNA expression in the mammalian ovary. Bisphenol-
A (BPA) is an environmentally ubiquitous endocrine
system-disrupting chemical. Veiga-Lopez et al. studied
the effect of BPA on mRNA and miRNA expression and
reported that BPA increased CYP19 and 5α-reductase
mRNA expression, disrupted the sheep ovarian tran-
scriptome and altered the fetal ovarian miRNA expres-
sion profile [55]. In addition, ovarian miRNA expression,
including miR-497 and miR-15b, is influenced by pre-
natal testosterone treatment [56].
miRNAs and ovarian disorders
Recent studies have reported that differential expression
and dysregulation of miRNAs are associated with ovar-
ian diseases, such as ovarian cancer, PCOS and prema-
ture ovarian failure (POF) [13, 57].
miRNAs and ovarian cancer
Ovarian cancer is the most lethal gynecological malig-
nancy. Recently, multiple studies have profiled miRNAs
in ovarian cancer compared with normal tissues to
identify differentially expressed miRNAs [58–61]. Iorio
et al. [58] were the first to compare genome-wide
miRNA expression profiles from both ovarian cancer
tissues and normal ovary tissues and reported that
miRNA expression was differentially regulated in the
two groups; miR-200a, miR-141, miR-200c, and miR-
200b were overexpressed in ovarian cancer, and miR-
199a, miR-140, miR-145, and miR-125b1 were the most
downregulated miRNAs. These four downregulated
miRNAs had a common target oncosuppressor, namely,
BRCA1-associated protein (BAP1). Shapira and his col-
leagues [60] collected presurgical plasma samples from
women with confirmed serous epithelial ovarian cancer,
benign neoplasms and no known pelvic mass to assess
miRNA profiles. Twenty-two miRNAs were differen-
tially expressed between healthy controls and the ovar-
ian cancer group, whereas a six-miRNA-profile subset
(miR-106b, miR-126, miR-150, miR-17, miR-20a, and
miR-92a) could distinguish between benign and ovarian
cancer patients.
miRNAs play significant roles in the early diagnosis,
prognosis and chemotherapy sensitivity of ovarian
cancer. A recent study related to stage I ovarian tumors
revealed that miR-30a and miR-30a* are markers of
clear-cell tumors, whereas miR-192 and miR-194 are
markers of mucinous tumors [62]. Langhe et al. [63] re-
ported that 4 miRNAs (let-7i-5p, miR-122, miR-152-5p
and miR-25-3p) are significantly downregulated in ovarian
cancer patients. The target genes of these differentially
expressed miRNAs are involved in WNT signaling,
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AKT/mTOR and TLR-4/MyD88, which play roles in
ovarian carcinogenesis and chemoresistance. These re-
sults indicate the roles of let-7i-5p, miR-122, miR-152-5p
and miR-25-3p as diagnostic biomarkers in ovarian
cancer.
In a prognostic study, Merritt investigated Dicer mes-
senger RNA (mRNA) and Drosha levels in invasive epi-
thelial ovarian cancer patients and compared the results
with clinical outcomes. Low Dicer expression was sig-
nificantly associated with advanced tumor stage, and low
Drosha expression was associated with suboptimal surgi-
cal cytoreduction [64]. Another study by Marchini [65]
et al. confirmed that miR-200c downregulation is associ-
ated with overall and progression-free survival (PFS) in-
dependent of clinical covariates in stage I epithelial
ovarian cancer. Further research by Park [66] identified
the pivotal role of the miR-200 family in the epithelial-
to-mesenchymal transition (EMT), which is a decisive
step toward tumor cell invasion and metastasis and is
positively correlated with poor patient prognosis. miR-
200 suppressed the EMT by directly downregulating the
expression of the E-cadherin transcriptional repressors
ZEB1 and ZEB2 (SMAD-interacting protein 1, SIP1),
thus reducing E-cadherin expression and promoting the
EMT [66]. In studies of the serous subtype of epithelial
ovarian cancer, miR-506 was found to be a robust EMT
inhibitor through direct targeting of the E-cad repressor
SNAI2 [67], the vimentin gene (VIM) and N-cad gene
(CDH2) [68], suggesting that miR-506 inhibits multiple
targets in the EMT network and is associated with good
prognosis in epithelial ovarian cancer. Regarding the
therapeutic role of miRNAs in ovarian cancer, Gu et al.
[69] reported that three miRNAs (hsa-miR-146a, hsa-miR-
148a and hsa-miR-545) are predominantly expressed in
patients with wild-type BRCA1/2 ovarian cancers who
may benefit from platinum-based chemotherapy. These
miRNAs target BRCA1/2, which is the key gene involved
in the DNA damage response and DNA repair processes,
leading to the increasing sensitivity of cancer cells to
chemotherapy [69].
miRNAs and PCOS
PCOS is a multifactorial endocrine disorder affecting ap-
proximately 5–10 % of all women of reproductive age
[70–72]. Hossain et al. [73] established a rat PCOS
model via dihydrotestosterone (DHT) induction to in-
vestigate PCOS-associated ovarian miRNA expression
profiles and found that the differential expression of
regulatory miRNAs is associated with PCOS pathogen-
esis in rat ovaries. This study showed that 25 miRNAs,
which were designated as ovarian miRNAs, were highly
and differently expressed in the ovary in PCOS and nor-
mal rats. Most of the miRNAs in the ovary that promote
the cystic conditions are localized in the follicular theca
cells of DHT-treated ovaries. Further research explored
the dysregulated molecular pathways related to altered
miRNAs in PCOS rat ovaries. miR-222 was confirmed to
be expressed in theca cells by in situ localization, and
the expression was reported to be repressed by andro-
gens, which regulate cell proliferation by targeting P27/
kip1. In addition, miR-222 overexpression was associated
with reduced ERα protein and signaling as well as ex-
pression of the ERα target genes. The findings may offer
new insights for PCOS pathogenesis research [73]. Sang
et al. [74] assessed miRNA expression in human follicular
fluid of PCOS patients and identified numerous miRNAs
that play important roles in steroidogenesis. miR-132 and
miR-320 are expressed at a significantly reduced level in
the follicular fluid of polycystic ovary patients compared
with healthy controls. In addition, miR-132, miR-320,
miR-520c-3p, miR-24 and miR-222 regulate estradiol con-
centrations, and miR-24, miR-193b, and miR-483-5p
regulate progesterone concentrations in PCOS patients.
PCOS is characterized by polycystic ovaries, hyperan-
drogenism, insulin resistance (IR) and chronic anovulation
[75]. miRNAs are also involved in metabolic processes.
For example, miR-93 is overexpressed in PCOS and is as-
sociated with decreased GLUT4 and increased IR [76].
Additionally, miRNA-21, miRNA-27b, miRNA-103 and
miRNA-155 play important roles in metabolic processes
and are influenced by obesity and circulating androgen
concentrations in PCOS patients [77].
miRNAs and premature ovarian failure (POF)
POF is an ovarian disorder of multifactorial origin that
is defined as the occurrence of amenorrhea, hypergona-
dotropism and hypoestrogenism in women aged younger
than 40 years [78]. Recent studies based on samples
from both plasma and ovarian tissues have identified
miRNAs involved in POF development. Dang et al.
reported reduced miR-22-3p plasma levels in POF of
Han Chinese patients compared with control women. In
addition, decreased miR-22-3p expression was correlated
with the diminished ovarian reserve [79]. Our previous
studies identified the differentially expressed miRNAs in
plasma between POF and normal cycling women and
the roles of miRNAs in regulating many signaling path-
ways [13]. miR-23a is upregulated in the plasma of POF
patients, and miR-23a overexpression decreases XIAP
and caspase-3 levels and increases apoptosis in human
granulosa cells. These results indicate that miR-23a po-
tentially induces granulosa cell apoptosis by inhibiting
XIAP expression both at the mRNA and protein levels
in vitro [13]. In addition, Kuang et al. [80] identified a
total of 63 upregulated and 20 downregulated miRNAs
in ovarian tissue samples from 4-vinylcyclohexene diep-
oxide (VCD)-induced rat POF models compared with
samples from normal rats. Further studies confirmed
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that miR-29a and miR-144 are downregulated in POF
tissues and potentially regulate prostaglandin biosyn-
thesis by targeting PLA2G4A, whereas various upregu-
lated miRNAs, including miR-27b, miR-190, miR-151
and miR-672, are involved in the apoptotic process and
hormone stimulation [80].
Recent studies indicate that miRNA single-nucleotide
polymorphisms (SNPs) are associated with disease suscep-
tibility. A study related to miRNA polymorphism analysis
identified the association between combined genotypes
and haplotypes of miR-146aC>G, miR-196a2T>C, and
miR-499A>G and POF in Korean women; the results
indicate that the transcriptional aberration of miR-146a
and miR-196a2 induced by miRNA SNPs is potentially
involved in POF development [81].
Conclusions and future directions
miRNAs are post-transcriptional regulators in both
physiological and pathological processes. A single
miRNA may target several mRNAs, and a single mRNA
may be regulated by multiple miRNAs. Many miRNAs
are expressed in the ovary and are involved in ovarian
follicle development, atresia, ovulation and ovarian ste-
roidogenesis by targeting specific genes and regulating
various signaling pathways. miRNAs also play important
roles in ovarian diseases. However, studies on miRNAs
in the ovary have mainly focused on expression profiles
rather than their regulation and function networks.
Identifying miRNAs that are specific to different repro-
ductive organs will help guide researchers to better
understand the underlying mechanisms of reproductive
disorders. In addition, identifying upstream or additional
regulators of miRNAs, their target genes and their roles
in the related signaling pathways will further shed light
on the importance of specific miRNAs for both the de-
velopment and function of the ovary, paving the way for
new therapeutic strategies by controlling the key factors
in the regulatory networks. Furthermore, recent studies
have demonstrated that SNPs located in miRNA genes
or miRNA binding sites potentially modify miRNA regu-
lation, thus affecting phenotypes and disease susceptibil-
ity. Therefore, a combination of miRNA expression
profiles with genome-wide SNP genotyping might help
distinguish among potential disease-related biomarkers.
A better understanding of the regulation of ovarian
function by miRNAs may offer a theoretical foundation
for ovarian diseases.
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